Kalra Sanjay, Zargar Abdul Hamid, Sridhar G R, Das Ashok Kumar, Ahmed Jamal, Mohan Jagdish Chander, Vijayakumar G, Kumar Ajay, Sahay Rakesh Kumar, Ayer Vageesh, Pandit Kaushik, Bantwal Ganapathi, Srinivas Arun, Unnikrishnan A G, Jindal Sushil, Ray Saumitra, Baruah Manash P, Ganguly Kajal, Mittal Sachin, Joshi Ameya, George Joe, Hk Ganesh, Kapoor Nitin, Ramakrishnan Santosh, Shah Chetan, Dhingra Atul, Sharma Balram
Bharti Hospital, Karnal, Haryana, India.
Centre for Diabetes and Endocrine Care, Srinagar, Jammu and Kashmir, India.
Clin Med Insights Endocrinol Diabetes. 2024 Feb 22;17:11795514231203911. doi: 10.1177/11795514231203911. eCollection 2024.
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.
维格列汀是一种二肽基肽酶-4（DPP-4）抑制剂，作为单药治疗、双联或三联联合治疗时，可有效降低2型糖尿病（T2DM）患者的糖化血红蛋白（HbA1c）水平。在印度，维格列汀常用于T2DM患者，因为它可降低血糖波动幅度均值（MAGE），低血糖风险较低且对体重无影响。维格列汀与二甲双胍的早期联合治疗对T2DM患者有效且耐受性良好，无论年龄或种族如何。鉴于已有的关于维格列汀的数据以及最新出现的临床证据，一群内分泌学家、糖尿病专家和心脏病专家召开了一次专家组会议，讨论维格列汀在T2DM管理中的作用及各种联合用药。本实用文件旨在指导医师和专家了解维格列汀用于启动和强化T2DM治疗的不同有效强度和剂型。
